Treatment of Moderate to Severe Alzheimer's Disease with Memantine
Clinical Efficacy
- Memantine shows statistically significant improvement in cognition scores for moderate to severe Alzheimer's disease as measured by the Severe Impairment Battery (SIB) 1, 2
- Studies demonstrate statistically significant changes on the CIBIC-plus scale (global assessment) for patients with moderate to severe Alzheimer's disease 1, 2
- Limited evidence shows improvement in quality of life, caregiver burden, and resource utilization 1, 2
- Combination therapy with cholinesterase inhibitors has shown additional benefits, with patients receiving memantine plus donepezil showing significant benefits on measures of cognition, activities of daily living, global outcome, and behavior compared to donepezil alone 3
Adverse Effects and Monitoring
- Common adverse events include nausea, dizziness, diarrhea, and agitation 1, 2
- Withdrawal rates due to adverse effects range from 9-12% in treatment groups (compared to 7-13% in placebo groups) 1, 2
Duration of Treatment and Discontinuation
- Consider discontinuation if there has been clinically meaningful worsening of dementia over the past 6 months without other medical conditions or environmental factors contributing to the decline 4
- Consider discontinuation if no clinically meaningful benefit observed at any time during treatment 4
- Consider discontinuation if the individual has severe or end-stage dementia (dependence in most basic activities of daily living, inability to respond to environment, or limited life expectancy) 4
- When discontinuing memantine, a gradual approach is recommended, reducing dose by 50% every 4 weeks until reaching the initial starting dose 4
Important Clinical Considerations
- Memantine should be discontinued for indications other than Alzheimer's disease, Parkinson's disease dementia, dementia with Lewy bodies, or vascular dementia 4
- For patients with neuropsychiatric symptoms (psychosis, agitation, aggression), continue memantine if there has been a clinically meaningful reduction in these symptoms, even if there is evidence of cognitive and functional decline 4
Memantine Dosing Considerations for Alzheimer's Disease
Patient Selection for Dose Escalation
- The American Academy of Neurology recommends considering dose escalation to 20mg daily in patients with moderate-to-severe Alzheimer's disease who have not achieved optimal response on lower doses, with careful assessment of renal function, hepatic function, and current tolerability 5, 6, 7
- Poor medication adherence is a criterion for considering discontinuation rather than dose escalation, as stated by the Alzheimer's Association 5, 6, 7
Contraindications for Dose Escalation
- The American Geriatrics Society suggests considering discontinuation rather than dose escalation in patients with clinically meaningful worsening over the past 6 months without other contributing factors, no clinically meaningful benefit observed at any time during treatment, severe or end-stage dementia, or development of intolerable side effects 5, 6, 7